Clinical Trial Update: Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine [Phase 1, Phase 2]

View source ↗

Summary

Phase II extension study of oral rigosertib in combination with azacitidine in myelodysplastic syndrome and related conditions has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome
• Myelomonocytic Leukemia

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Rigosertib (rigosertib)

Snippet

Sponsor: Traws Pharma, Inc. | Conditions: Myelodysplastic Syndrome, Acute Myeloid Leukemia | Phase 1, Phase 2 | Status: COMPLETED